Cidara Therapeutics
Cidara Therapeutics is developing innovative therapies.
Launch date
Employees
Market cap
$80.4m
Enterprise valuation
($80m) (Public information from Sep 2024)
Share price
$11.62 CDTX
San Diego California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 12.1m | 49.6m | 64.3m | 63.9m | 7.1m | 42.9m | 53.3m |
| % growth | (42 %) | 311 % | 30 % | (1 %) | (89 %) | 504 % | 24 % |
| EBITDA | (71.6m) | (42.3m) | (29.7m) | (24.4m) | - | - | - |
| % EBITDA margin | (594 %) | (85 %) | (46 %) | (38 %) | - | - | - |
| Profit | (72.1m) | (42.5m) | (29.8m) | (22.9m) | (168m) | (119m) | (139m) |
| % profit margin | (598 %) | (86 %) | (46 %) | (36 %) | (2369 %) | (277 %) | (261 %) |
| EV / revenue | 7.3x | 1.7x | 0.8x | 1.1x | 11.8x | 1.9x | 1.6x |
| EV / EBITDA | -1.2x | -2.0x | -1.8x | -3.0x | - | - | - |
| R&D budget | 68.0m | 73.1m | 75.5m | 68.5m | - | - | - |
| R&D % of revenue | 564 % | 147 % | 117 % | 107 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$32.0m | Series A | ||
$42.0m | Series B | ||
| N/A | N/A | IPO | |
$20.0m | Post IPO Debt | ||
$6.9m | Grant | ||
| N/A | $20.2m | Post IPO Equity | |
N/A | Grant | ||
| N/A | $35.0m | Post IPO Equity | |
* | N/A | $17.3m | Post IPO Equity |
* | N/A | $240m | Post IPO Equity |
| Total Funding | $80.9m | ||
Related Content
Recent News about Cidara Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.